Wall Street equity research analysts covering X4 Pharmaceuticals (NASDAQ: XFOR) maintain a strong consensus rating, heavily leaning toward a Strong Buy view. Analysts emphasize the strong commercial potential of their rare disease therapies, recent European regulatory approvals, and advancing late-stage clinical programs. However, biotechnology stocks carry inherent regulatory and clinical trial risks. What is your risk tolerance and portfolio time horizon? Consulting a certified financial advisor is recommended before making investment choices.